Skip to content
CompoundSci
All peptides
Research vial labelled PT-141, a Melanocortin and sexual peptide studied in preclinical and clinical literature

PT-141

Bremelanotide

Bremelanotide is an approved melanocortin agonist for hypoactive sexual desire disorder in premenopausal women.

FDA approved as Vyleesi. Transient blood pressure rise and nausea are the documented effects to read about.

General profile

Class
Melanocortin and sexual
Evidence
Strong human evidence
Studied dose range
0.5–1.75 mg
Frequency in protocols
As needed, not more than once in 24 hours
Route
Subcutaneous
Half life
~2.7 hours
Reconstitution
2 mL bacteriostatic water per 10 mg vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the evening window

As needed, never more than once in 24 hours

Onset is slow and effects last hours. The label limits it to one dose in 24 hours and eight per month because of the blood pressure response.

Reported cycle: 4 weeks on, run continuously in trials

Used episodically rather than cycled, with a labelled ceiling of one dose in 24 hours and eight per month.

Watch for: Blood pressure rise, nausea and flushing in the first hours. Anyone with uncontrolled hypertension should skip it.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopBody level hard stop

    PT-141 + The window right after cardiac surgery

    Not alongside an active cardiac recovery regimen

    Bleeding risk and the cardiac drug regimen come first. Pro-angiogenic and vasodilatory compounds can clash with that care. Physician territory, not a timing problem.

  • Hard stopBody level hard stop

    PT-141 + Nitrates, and sildenafil or tadalafil taken with nitrates

    Never with nitrate medication in the picture

    Nitroglycerin, isosorbide and poppers combined with vasoactive agents can drop blood pressure to dangerous levels.

  • Hard stopTiming

    PT-141 + Melanotan II

    Additive blood pressure and nausea

    Both are melanocortin agonists that transiently raise blood pressure and cause nausea. Together those effects stack in the same window.

  • Separate syringesSame day fine, same syringe not

    PT-141 + Oxytocin

    Not at full doses together

    Both flush hard. Combined full doses stack redness, nausea and vomiting rather than adding any benefit.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how PT-141 fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: Two phase 3 randomised trials.

Open questions: Effect sizes are modest and transient blood pressure changes are documented.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature